3-benzyl-(5Z)-(3,4,5-trimethoxybenzylidene)thiazolidine-2,4-dione | 1621470-92-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-benzyl-(5Z)-(3,4,5-trimethoxybenzylidene)thiazolidine-2,4-dione
• 英文别名: 3-Benzyl-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazolidine-2,4-dione；(5Z)-3-benzyl-5-[(3,4,5-trimethoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 1621470-92-5
• 化学式: C₂₀H₁₉NO₅S
• 分子量: 385.441
• InChiKey: NDKWUVQDURAFKU-BOPFTXTBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  90.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4,5-三甲氧基苯甲醛 在 potassium carbonate 、 β-丙氨酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-benzyl-(5Z)-(3,4,5-trimethoxybenzylidene)thiazolidine-2,4-dione
  参考文献：
  名称：

  Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds

  摘要：

  Δ2-Troglitazone derivatives were shown to exhibit anti-proliferative activity in a PPARγ-independent manner. We prepared various compounds in order to increase their potency and decrease their toxicity towards non-malignant primary cultured hepatocytes. Many compounds induced viabilities less than 20% at 10 μM on various cancer cell lines. Furthermore, five of them showed hepatocyte viability of 80% or more at 200 μM. In addition, compounds 17 and 18 exhibited promising maximum tolerated doses on a murine model, enabling future investigations.

  DOI：

  10.1016/j.ejmech.2014.06.015

文献信息

• Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds
  作者：Andrea Bordessa、Christelle Colin-Cassin、Isabelle Grillier-Vuissoz、Sandra Kuntz、Sabine Mazerbourg、Gauthier Husson、Myriam Vo、Stéphane Flament、Hélène Martin、Yves Chapleur、Michel Boisbrun

  DOI：10.1016/j.ejmech.2014.06.015

  日期：2014.8

  Δ2-Troglitazone derivatives were shown to exhibit anti-proliferative activity in a PPARγ-independent manner. We prepared various compounds in order to increase their potency and decrease their toxicity towards non-malignant primary cultured hepatocytes. Many compounds induced viabilities less than 20% at 10 μM on various cancer cell lines. Furthermore, five of them showed hepatocyte viability of 80% or more at 200 μM. In addition, compounds 17 and 18 exhibited promising maximum tolerated doses on a murine model, enabling future investigations.